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LDL in patients with subclinical hypothyroidism
shows increased lipid peroxidation
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Abstract
Background: Population-based studies have demonstrated that subclinical hypothyroidism (SCH) is an independent risk
factor for atherosclerosis (OR = 1.9). However, this connection cannot be entirely explained by dyslipidemia accompanied
by SCH. Lipid peroxidation also plays an important role in the development of atherosclerosis. In this study, we aimed to
evaluate oxidative stress in SCH patients, as measured according to concentrations of hydroxy-octadecadienoic acids
(HODEs) and hydroxy-eicosatetraenoic acids (HETEs) in both plasma and low density lipoproteins (LDL).
Subjects and methods: The concentrations of HODEs and HETEs in both LDL and plasma were examined in euthyroid
(n = 10), mild SCH (4.5≤ TSH <10 mU/L, n = 10), and significant SCH (TSH≥ 10 mU/L, n = 10) subjects, using a liquid
chromatograph-electrospray ionization- mass spectrometer. Then, we explored the relationship among LDL oxidation,
TSH levels, and carotid intima-media thickness (IMT), a biomarker of subclinical atherosclerosis.
Results: Serum LDL-C levels and mean-IMT in the significant SCH group were higher than in the euthyroid group
(p < 0.05). The HODE and HETE concentrations clearly increased in the significant SCH patients compared with the
euthyroid subjects, but there was no difference between the mild SCH and euthyroid groups. Among all subjects, linear
and significant positive correlations were identified between TSH and mean-IMT after adjustment for confounding
factors (r = 0.480, p = 0.018). Both 9-HODE (r = 0.376, p = 0.041) and 13-HODE (r = 0.447, p = 0.013) in LDL were linearly
and positively correlated with TSH. The concentrations of HODEs (both 9-HODE and 13-HODE) in LDL were much higher
in the thickened IMT group than in the normal IMT group (p = 0.017 and 0.015, respectively). HODEs in LDL were also
positively associated with mean-IMT.
Conclusions: Our findings showed that lipid peroxidation was higher in the significant SCH patients than in the
euthyroid subjects, which suggested that qualitative as well as quantitative changes in serum lipids resulting from SCH
may add to atherosclerosis risk.
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Background
Subclinical hypothyroidism (SCH), which is defined as
elevated serum thyroid-stimulating hormone (TSH) and
normal serum free thyroxine (FT4), is becoming a global
health problem because of its increasing prevalence and
potential deleterious effects. SCH occurs in 4–20 % of
the adult population, even more than the population
with diabetes mellitus and is increasing globally. More-
over, population-based studies demonstrate that both
the risk and mortality of coronary heart disease are in-
creased in SCH patients [1–3]. The reason may be that
SCH is an independent risk factor for atherosclerosis
(OR = 1.9), which was demonstrated in the Rotterdam
Study [4]. Although SCH is often accompanied by dys-
lipidemia, the increased concentration of serum lipids
does not necessarily result in atherosclerosis [5]. Indeed,
the quantitative alteration of lipid profiles in SCH
patients was still controversial [6, 7]. Increasing experi-
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mental and epidemiological evidence shows that lipid
peroxidation plays an important role in atherosclerosis
development. However, few studies have evaluated oxi-
dation in SCH patients.
The oxidation of LDL converts it into an atherogenic
form that contributes to the development of the
atherosclerotic lesion. One of the major pathways of
LDL oxidation is the lipoxygenase pathway by seeding
molecules that include hydroperoxyoctadecadienoic
acid (HPODE) and hydroperoxyeicosatetraenoic acid
(HPETE), which are subsequently reduced to their
hydroxyl derivatives hydroxy-octadecadienoic acids
(HODEs) and hydroxy-eicosatetraenoic acids (HETEs)
[8, 9]. Notably, these HODEs and HETEs enhance
atherogenicity [10, 11] and are considered reliable
oxidative stress biomarkers. Currently, the evidence
supporting increased oxidative stress in LDL among
SCH patients is scarce and indirect, mostly based on
increased plasma autoantibody levels against oxida-
tively modified LDL [12]. To our knowledge, there are
no data available on the alteration of HODEs and
HETEs in either LDL or plasma in SCH patients.
In the present study, we attempted to explore the status
of lipid peroxidation as measured by concentrations of
HODE and HETEs. We further explored the relationships
among lipid oxidation, TSH levels, and carotid intima-
media thickness (IMT), a biomarker of subclinical
atherosclerosis [13]. In addition, we compared the dif-
ferences in HODE and HETEs levels in plasma and
LDL, respectively, attempting to identify a better surro-
gate marker for IMT. Our findings may also help fully
elucidate the mechanism that underlies the association
between high atherosclerosis risk and SCH from a new
perspective.
Results
Characteristics of the study groups
The clinical and laboratory data are depicted in Table 1.
According to their serum TSH concentrations, the sub-
jects were divided into 3 groups: euthyroid, mild SCH,
and significant SCH. There was no significant difference
among the 3 groups with regard to serum FT3 or FT4
levels. Serum LDL-C levels and mean-IMT in the signifi-
cant SCH group were higher than they were in the eu-
thyroid group (p < 0.05), whereas no differences were
found between the mild SCH and euthyroid groups
(p > 0.05). There were no significant differences between
groups for other factors as well, including age, gender
distribution, BMI, systolic and diastolic pressure, fasting
plasma glucose, TC, HDL-C, and TG levels (p > 0.05).
As shown in Additional file 1: Table S1, the TC con-
tent in LDL increased gradually but not significantly
among the euthyroid, mild SCH, and significant SCH
Table 1 Clinical and laboratory data of the studied groups
Variable Euthyroid Mild SCH Significant SCH pa pb pc
n 10 10 10 NA NA NA
Gender (male/female) 4/6 3/7 2/8 0.879
Age (years) 52.0 ± 5.7 53.2 ± 5.4 57.3 ± 5.5 1.000 0.125 0.329
BMI (kg/m2) 24.0 ± 1.6 24.4 ± 1.8 24.4 ± 1.5 1.000 1.000 1.000
SBP (mmHg) 130.0 ± 17.8 129.6 ± 12.4 126.4 ± 21.5 1.000 1.000 1.000
DBP (mmHg) 77.1 ± 8.5 80.4 ± 6.8 75.3 ± 5.6 0.915 1.000 0.353
Mean-IMT (mm) 0.75 ± 0.09 0.82 ± 0.14 0.99 ± 0.32 1.000 0.045 0.193
FBG (mmol/l) 5.41 ± 0.63 5.72 ± 0.65 5.34 ± 0.31 0.477 0.946 0.202
FT3 (pmol/L) 4.79 ± 0.39 5.23 ± 0.77 4.89 ± 0.41 0.210 0.825 0.376
FT4 (pmol/L) 14.33 ± 1.42 14.55 ± 1.59 13.79 ± 1.47 1.000 1.000 0.652
TSH (mIU/L) 3.32 ± 0.57 5.92 ± 1.47 12.98 ± 3.23 0.013 0.000 0.000
TC (mmol/l) 5.15 ± 0.43 5.75 ± 1.00 5.81 ± 1.13 0.117 0.183 0.990
HDL-C (mmol/l) 1.45 ± 0.15 1.50 ± 0.36 1.61 ± 0.42 0.896 0.429 0.762
LDL-C (mmol/l) 2.78 ± 0.35 3.16 ± 0.61 3.43 ± 0.59 0.372 0.032 0.779
TG (mmol/l) 0.92 ± 0.07 1.16 ± 0.27 1.15 ± 0.31 0.117 0.142 1.000
Continuous and categorical variables data are expressed as the mean ± standard deviations and real number of subjects, respectively. The statistical p value was
generated by one-way ANOVA with Bonferroni correction as the post-hoc test. The χ-square test was employed to compare gender distribution. P arepresents the
mild SCH vs euthyroid group, P brepresents the significant SCH vs euthyroid group, and P crepresents the significant SCH vs mild SCH group. Abbreviation: mild
SH, mild subclinical hypothyroidism group; significant SCH, significant subclinical hypothyroidism group; BMI body mass index, mean-IMT mean carotid
intima-media thickness, FBG fasting blood glucose, FT3 free T3, FT4 free T4, TSH thyroid stimulating hormone, TC total cholesterol, HDL-C high-density lipoprotein,
LDL-C low-density lipoprotein, TG triglyceride, NA not applicable
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groups (p > 0.05). The TG content in LDL was also not
significantly different.
A positive relationship between TSH and mean-IMT levels
Carotid IMT is strongly associated with atherosclerosis.
An IMT greater than 0.9 mm is almost certainly indicative
of atherosclerosis and increased risk of cardiovascular
disease [14]. Notably, among all subjects, linear and signifi-
cant positive correlations were identified between TSH
and mean-IMT (r = 0.401, p = 0.028). Interestingly, the cor-
relations remained significant even after we adjusted for
age, gender, BMI, TC, HDL-C,LDL-C, and TG (r = 0.480,
p = 0.018) (Fig. 1). This finding suggests an association be-
tween SCH and the risk for atherosclerosis.
Lipid peroxidation increased in SCH patients
Lipid peroxidation plays an important role in developing
atherosclerosis. Notably, HETEs and HODEs are the
stable end products of lipid peroxidation. Subsequently,
we determined the HODEs and HETEs in plasma and
LDL, respectively among the euthyroid, mild SCH, and
significant SCH groups.
As shown in Fig. 2, the concentrations of HODEs
(both 9-HODE and 13-HODE) in plasma clearly in-
creased in the significant SCH patients compared with
the euthyroid subjects, and there was no difference
between the mild SCH and euthyroid groups. Similar
findings were also obtained with respect to the HODE
concentrations in LDL. However, the results for the
HETE concentrations in plasma were not consistent
with those for LDL. Compared with the euthyroid sub-
jects, plasma 5-HETE and 12-HETE levels in the
significant SCH patients were higher. Notably, no signifi-
cant differences were detected with regard to the HETE
concentrations in LDL among the 3 groups.
HODEs in LDL were positively associated with TSH
Then, we evaluated the relationship between HODEs in
LDL and TSH. As shown in Fig. 3, the Spearman’s cor-
relation analysis revealed that both 9-HODE (r = 0.376,
p = 0.041) and 13-HODE (r = 0.447, p = 0.013) in LDL
were linearly and positively correlated with TSH, which
indicated that lipid peroxidation in LDL was signifi-
cantly aggravated with the elevation of TSH.
HODEs in LDL might be more sensitively indicative of
atherosclerosis
Then, we detected the concentrations of HETEs and
HODEs in both plasma and LDL to evaluate their role
in the indication of atherosclerosis.
As mentioned above, we divided all subjects into two
groups according to their IMT: normal (max-IMT ≤
0.9 mm) (n = 16) and thickened (max-IMT > 0.9 mm)
(n = 14). Notably, the HODE concentrations (both
9-HODE and 13-HODE) in LDL were much higher in
the thickened IMT group than they were in the normal
group (Additional file 2: Figure S1, p = 0.017 and 0.015,
respectively). No difference was found in plasma
HODE levels between the normal and thickened IMT
groups. Moreover, there were no significant differences
in the HETE concentrations (5-, 12-, and 15-HETE) in
either plasma or LDL between the normal and thick-
ened IMT groups (data not shown).
In addition, we also evaluated the relationship between
HODEs in LDL and mean-IMT using Spearman’s correl-
ation analysis (Additional file 3: Figure S2). Interestingly,
a positive and significant correlation was obtained be-
tween mean-IMT and the concentration of 9-HODE in
LDL (r = 0.479, p = 0.007); as well as the concentration
of 13-HODE in LDL (r = 0.447, p = 0.013).
These data suggested that (1) compared with HETEs,
HODEs were a more reliable biomarker for atherosclerosis
and (2) compared with HODEs in plasma, HODEs in LDL
might be more sensitively indicative of atherosclerosis.
Discussion
Our study confirmed that SCH, especially significant
SCH (TSH ≥ 10 mIU/L), was associated with a high risk
of atherosclerosis. Indeed, previous studies have sug-
gested the connection between SCH and atherosclerosis.
However, this connection cannot be entirely explained
by dyslipidemia accompanied by SCH. Our findings
seem to present a more plausible explanation for this
connection from a new perspective.
Consistent with our results, population-based studies
have demonstrated that SCH is an independent risk
Fig. 1 Correlation analysis between TSH and mean-IMT in the study
population. Partial correlation analysis after adjustment for age,
gender, BMI, TC, HDL-C, LDL-C and TG: r = 0.480, p =0.018
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factor for atherosclerosis (OR = 1.9) and myocardial in-
farction (OR = 3.1) [4]. However, the changes in the lipid
profiles of SCH patients were still controversial. Although
some studies have demonstrated that total cholesterol and
LDL-C levels are elevated in patients with SCH [6], others
have not shown any effect of SCH on these lipid measure-
ments. In the National Health and Nutrition Examination
Survey III (n = 8586), SCH was not associated with
changes in serum cholesterol or triglyceride levels after
adjustment for confounding factors [7]. In a cross-
sectional study of 7000 thyroid clinic outpatients, total
cholesterol and LDL-C were clearly elevated in overt
hypothyroid patients, but there were no significant
differences in serum total cholesterol, LDL-C, HDL-C, or
triglyceride levels between SCH patients and the euthyroid
control group [15]. Therefore, the association between
SCH and atherosclerosis cannot be entirely explained by
dyslipidemia accompanied by SCH. Our findings showed
that LDL-C levels and lipid peroxidation markedly in-
creased mainly in significant SCH patients compared with
euthyroid subjects, which suggested that qualitative as
well as quantitative changes in serum lipids resulting from
SCH may add to atherosclerosis risk.
To the best of our knowledge, data on oxidative stress
in SCH patients are still limited and controversial. In
one study, SCH patients were found to be associated
Fig. 2 HODEs and HETEs in plasma and LDL respectively among the euthyroid, mild SCH, and significant SCH groups. The concentrations of
9- and 13- HODE in plasma (a) and in LDL (b) among the euthyroid, mild SCH, and significant SCH groups; the concentrations of 5-, 12- and
15-HETE in plasma (c) and in LDL (d) among the euthyroid, mild SCH, and significant SCH groups. Data are means ± SEM (n = 10 participants per
group). Compare with euthyroid subjects: *p < 0.05 **p < 0.01 mild SCH compare with significant SCH :△p < 0.05 △△p < 0.01. Abbreviation: mild
SCH, mild subclinical hypothyroidism group; significant SCH, significant subclinical hypothyroidism group; HODE, hydroxy-octadecadienoic acid;
HETE, hydroxy-eicosatetraenoic acid
Fig. 3 Correlation analysis between HODEs in LDL and TSH in the study population. Spearman’s correlation analysis indicated TSH levels were linearly
and positively correlated with 9-HODE in LDL (r = 0.376, p = 0.041) and 13-HODE in LDL (r = 0.447, p = 0.013) respectively. Abbreviation: HODE,
hydroxy-octadecadienoic acid
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with increased oxidative stress manifested by reduced
arylesterase activity and elevated catalase (free-radical
scavenging enzyme) activity. Arylesterase, one of the
enzymatic activities of paraoxonase-1, is known to play a
protective role against the peroxidation of LDL and
other lipoproteins. However, no significant correlations
were observed after TC levels were controlled for.
Accordingly, oxidative stress in SCH seemed to be
induced by hypercholesterolemia secondary to thyroid
dysfunction but not hypothyroidism per se [16]. Two
other studies showed that malondialdehyde, a lipid
peroxidation marker, was increased in SCH patients,
which suggested increased oxidative stress in SCH states
[17, 18]. Additionally, superoxide dismutase (free-radical
scavenging enzyme) levels were found to be higher in
SCH patients and shown to decrease after L-T4 treat-
ment for 3 months [19]. Nevertheless, little is known
about LDL susceptibility to oxidation in SCH patients
and its relation to TSH levels. Here, we further
determined the lipid peroxidation markers, mainly
HETEs and HODEs, in both LDL and plasma in SCH
patients and euthyroid controls.
Our data revealed that 9-HODE and 13-HODE, derived
from linoleic acid, significantly increased in significant
SCH patients in both plasma and LDL compared with
those of the control subjects. Meanwhile, the concentra-
tions of 5-HETE and 12-HETE were significantly
increased in SCH patients compared with control subjects
only in plasma but not in LDL. These results were in
agreement with those from previous studies. Patients with
essential hypertension have been reported to show
increased plasma 13-HODE levels, presumably reflecting
increased oxidative stress [20]. Recently, Colas et al. [21]
demonstrated that oxidation products of linoleic acid
(HODEs) could be better markers of lipid peroxidation
than those of arachidonic acid, such as total HETEs and
F2-isoprostanes in LDL in obese patients with metabolic
syndrome. Linoleic acid occurs at a ratio of roughly 7:1
compared with arachidonic acid in the LDL particle [22]
and therefore may be the predominant target for
peroxidation. Meanwhile, HETEs are more prone to fur-
ther oxidation than HODEs. Because of the high levels of
linoleic acid and high stability of 9- and 13-HODE, these
two hydroxy acids are enriched in naturally occurring lipid
peroxidation processes to a greater extent than any other
lipid peroxidation products and are nearly ideal markers
for lipid peroxidation [23, 24]. Notably, our results also
showed that HODEs in LDL were positively associated
with TSH and might be more reliably and sensitively indi-
cative of atherosclerosis, which might substantiate
evidence for an association among lipid peroxidation,
SCH, and atherosclerosis.
The pathogenesis of atherosclerosis in SCH patients can
be partially explained by the increased 9- and 13-HODE
in LDL. Nagy et al. identified 9-HODE and 13-HODE,
two of the major oxidized lipid components of oxLDL, as
endogenous activators and ligands of PPARγ, which regu-
lates the expression of CD36 in macrophages [25]. This
suggested that 9- and 13- HODE may play a direct role in
the regulation of macrophage gene expression during
atherogenesis. Additionally, 9- and 13-HODE reduce
monocyte CCR2 expression through pathways involving
PPARγ, which may help retain monocytes at sites of
inflammation such as atherosclerotic lesions. This may ac-
celerate atherogenesis [26]. In contrast, native linoleic acid
without oxidative modification had no effect. Increased
HODE levels thus contribute to atherosclerosis progres-
sion and the risk of clinical events such as myocardial
infarction or stroke. Except for HODEs, Wigren et al.
reported that 5- and 12-HETE could also activate PPARγ
but were less potent [11]. Therefore, the increase in mul-
tiple HODEs and HETEs in LDL or plasma in patients
with SCH might present possible mechanisms for athero-
sclerosis in these patients. Additional studies are required
to explore whether TSH can regulate the production of
HODEs or HETEs.
Similar to a recent study [21], we found no significant
change in LDL levels of 5-,12- and 15-HETE in SCH pa-
tients compared with those of the euthyroid subjects,
although the exact mechanism is not clear. Proudfoot
et al. [27] reported that HDL is the major lipoprotein
carrier of plasma F2-isoprostanes (oxidation products of
arachidonic acids, just as HETEs) and that F2-
isoprostanes were significantly higher in HDL than in
LDL or VLDL after isolation via ultracentrifugation or
FPLC. As for HETEs, it is also necessary to determine the
distribution in different lipoproteins, which will be helpful
for elucidating the disparity of increased HETE levels in
plasma rather than in LDL in SCH patients.
The limitations of this study are the small sample size
and lipid peroxidation has not been performed after treat-
ment to subclinical hypothyroidsm. It is possible that the
enhanced lipid peroxidation noted may revert to normal
following correction of hypothyroidism with thyroxine
treatment. But, this needs to be established.
Taken together, our findings showed that lipid peroxida-
tion was markedly higher in significant SCH patients than
in euthyroid subjects, which suggested that qualitative as
well as quantitative changes in serum lipids resulting from
SCH may add to atherosclerosis risk. More prospective
studies are required to assess the effect of maintaining




The diagnosis of SCH was based on finding high TSH
levels associated with normal FT4 levels. Depending on
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the size of the increase in the serum TSH, subclinical
hypothyroidism can be classified as mild (serum TSH
concentrations of 4.5–10 mU/L) or significant (TSH
≥10 mU/L) [28]. Based on the exclusion criteria [17]
(diabetes mellitus, hypertension, obesity (body mass index,
BMI ≥ 28 kg/m2), ischemic heart disease, history of or
current smoking, active infection, malignancy, pituitary
and rheumatologic diseases, and usage of drugs that affect
the oxidant state or lipid parameters), we first included
160 newly diagnosed SCH patients from Ningyang
County, Shandong Province, from January to February
2013. Patients’ thyroid function was measured twice for
6 months interval to rule out laboratory error or transient
increases. Only 129 patients met the criteria of having two
consistent results and a final diagnosis of SCH. Among
these, we selected 20 SCH patients aged between 18 and
65 years using the random number table method: 10 mild
SCH patients and 10 age- and sex- matched significant
SCH patients. The control group consisted of 10 age- and
sex-matched healthy euthyroid subjects from the same
district. Histories, physical examinations, electrocardiog-
raphy, and routine chemical analysis revealed that the
control subjects showed no evidence of any disease. The
study was performed according to the Declaration of
Helsinki. All subjects signed an informed consent, vali-
dated and approved by the ethics committee of Shandong
Provincial Hospital affiliated to Shandong University. Eth-
ics committee of Shandong Provincial Hospital affiliated
to Shandong University specifically approved this study
(approval number: NO. 2013–105) (Additional file 4:
Figure S3).
Laboratory analysis
All of the measurements were performed in the clinical
laboratory of Shandong Provincial Hospital, affiliated
with Shandong University. Blood samples were col-
lected from all patients between 8:00 A.M. and 10:00
A.M. after a minimum of a 10-h fast. For LDL isolation
and monohydroxylated fatty acid detection, plasma was
separated via centrifugation at 1500 g for 10 min with
blood collected on EDTA. Then, 10 μM BHT was
added to plasma and immediately frozen at −80 °C
under nitrogen for further characterizations.
Chemiluminescent procedures (Cobas E610; Roche,
Basel, Switzerland) were employed to determine thyroid
function, including TSH, free triiodothyronine (FT3) and
free tetraiodothyronine (FT4). The laboratory reference
ranges were 0.27–4.2 mIU/L for TSH, 3.1–6.8 pmol/L for
FT3, and 12–22 pmol/L for FT4. The levels of plasma glu-
cose, total cholesterol (TC), triglyceride (TG), low-density
lipoprotein cholesterol (LDL-C), and high-density lipopro-
tein cholesterol (HDL-C) were determined using an Auto
Biochemical Analyzer (MODULAR-000GS; Roche, Basel,
Switzerland). Hypercholesterolemia was defined as a TC
value over 6.21 mmol/L, which is in accordance with the
National Cholesterol Education Program Adult Treatment
Panel III criteria (NCEP/ATPIII).
Carotid artery ultrasound
All patients underwent a carotid IMT examination using
a color ultrasonic diagnostic apparatus equipped with a
9 MHz linear-array transducer (Toshiba Aplio 500
Ultrasound Scanner) as described previously [29]. The
carotid IMT was defined as the viewable distance
between the blood-intimae and the media-adventitia in-
terfaces on the artery wall. Mean IMT (mean-IMT: the
mean of the three IMT measurements on each side) and
the maximum IMT (max-IMT: the highest IMT value
among the six segments studied) were assessed. Accord-
ing to current sonographic criteria, max-IMT ≤ 0.9 mm
was normal, and max-IMT > 0.9 mm was considered in-
dicative of thickened intima [29]. The study protocol
was based on current sonographic guidelines [30]. Each
scan was made by the same investigator, who was blind
to the patients’ clinical data.
LDL isolation using FPLC
LDL was isolated from plasma using gel filtration chro-
matography at 4 °C as previously described [31]. Briefly,
a AKTA purifier system fast–protein liquid chromatog-
raphy (FPLC) equipped with a Superose 6 10/300GL
column (GE Healthcare, Pittsburgh, PA, USA) was used
with a phosphate-buffered saline solution containing
1 mM EDTA and 0.02 % NaN3 as a running buffer. After
filtered plasma was loaded, chromatography was con-
ducted with a flow rate of 0.5 mL/min under a pressure
of 218 psi. Fractions of 0.5 mL were collected, and the
concentrations of TC and TG in the eluted fractions
were measured (Applygen Technologies Inc, Beijing).
The identified FPLC peaks are shown in Additional file 5:
Figure S4. The LDL fractions were concentrated on a Milli-
pore filter 30,000 MW (10 min at 4000 g). Then, the pro-
tein concentrations were determined using commercial kits
(Biocolor BioScience & Technology Company, Shanghai).
Enzymatic determination of TC and TG used commercial
kits (Applygen Technologies Inc, Beijing).
Quantification of total monohydroxylated fatty acids
using LC-ESI-MS
In order to quantify total monohydroxylated fatty acid
levels in plasma and LDL respectively, we prepared sam-
ples as described previously [32]. Briefly, following the
lipid extraction of plasma and LDL using a Folch solution
(chloroform-methanol, 2:1, v/v) containing 0.005 % (w/v)
BHT, dried extracts were subjected to methanol hydrolysis
with 1 M KOH for 30 min at 37 °C. After the PH of the
mixture was adjusting to 3.0 by adding 5 N HCl, we added
5 ng 15(S)-HETE-d8 and 10 ng 13(S)-HODE-d4 as
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internal standards after the mixture had cooled to room
temperature. After liquid-liquid extraction twice using
ethyl acetate, the two organic phases were combined and
the solvent was evaporated. Then, the residue was recon-
stituted into 100 μl of 80 % (v/v) LC mobile phase
A(2 mM NH4Ac, PH5.6) and 20 % (v/v) B(CH3CN
:MeOH,65:35,v/v). The solution was filtered using a Spin-
X filter and was then ready for LC-ESI-MS analysis.
Mass spectrometry was performed on a Thermo Vantage
triple-stage quadruple mass spectrometer (Thermo Fisher
Scientific, San Jose, CA, USA) equipped with electrospray
ionization (ESI).
Chromatographs were separated on a Thermo UltiM-
ate3000 series (Thermo Fisher Scientific, San Jose, CA,
USA). Chromatography was performed using a Unitary C
18 column (2.8 μm particle, 100 × 2.1 mm; Acchrom Tech-
nologies Co., Ltd). Mobile phase A consisted of 2 mM
NH4Ac in water (PH 5.6), and mobile phase B consisted of
65 % acetonitrile in methanol (v/v). The auotosampler was
set at 4 °C. The injection volume was 5 μl. The flow rate
was controlled at 0.2 mL/min. The gradient program was
as follows: 0–1 min, 20 % B; 1–20 min, linear gradient from
20 to 50 % B; 20–25 min, 50 % B; 25–30 min, linear gradi-
ent from 50–80 % B; 30–32 min, 80 % B; 32–35 min, linear
gradient from 80–100 % B; 35–37 min 100 % B; 37–
38 min, linear gradient from 100–20 % B; and 38–45 min
20 % B. The data acquisition and instrument control
were accomplished using Xcalibur software version 1.4
(Thermo Fisher Scientific, San Jose, CA, USA). The MS
was operated in negative ion mode using selective reac-
tion monitoring (SRM) by monitoring the characteristic
fragmentations. The transfer tube temperature was set
at 450 °C. The flow rate of the sheath gas was 55 arb.
The ion spray voltage was set at 4,500 V. The flow rate
of the auxiliary gas was 25 arb. Collision energy, declus-
tering potential and collision cell exit potential were
optimized for each compound to obtain optimum sen-
sitivity. The transitions monitored were mass-to-charge
ratio (m/z): 295.0→ 171.0 for 9-HODE; 295.1→ 194.8
for 13-HODE; 299.0→ 197.9 for 13(S)-HODE-d4;
319.1→ 115.0 for 5-HETE; 319.0→ 179.0 for 12-HETE;
319.1→ 175.0 for 15-HETE; 327.1→ 226.1 for 15(S)-
HETE-d8 (Additional file 6: Figure S5).
Statistical analysis
Statistical analyses were performed with SPSS version
17.0 for windows. One-way ANOVA with Bonferroni
correction as the post-hoc test was used to seek differ-
ences in variables among groups. Significance was de-
fined as a value of p < 0.05. If unstated, all values are
expressed as the mean ± SD for continuous variables.
Correlation coefficients were determined using the
Spearman correlation test.
Additional files
Additional file 1: Table S1. Lipid classes of LDL from euthyroid
subjects and mild and significant SCH patients. (DOC 46 kb)
Additional file 2: Figure S1. Compare of 9- and 13- HODE in plasma
and LDL in the normal and thickened intima groups respectively. A and
B: Compared of 9- and 13-HODE levels in plasma in the normal (n = 16)
and thickened intima (n = 14) groups; C and D: Compared of 9- and
13-HODE levels in LDL in the normal (n = 16) and thickened intima
(n = 14) groups. Abbreviation: HODE, hydroxy-octadecadienoic acid; IMT,
carotid intima-media thickness. (TIFF 420 kb)
Additional file 3: Figure S2. Correlation analysis between HODEs in LDL
and the mean-IMT levels in total study subjects. Spearman’s correlation
analysis indicated a positive and significant correlation between mean-IMT
and the concentration of 9-HODE in LDL (r = 0.479, p = 0.007) and 13-HODE
in LDL (r = 0.447, p = 0.013) respectively. Abbreviation: HODE, hydroxy-
octadecadienoic acid; mean-IMT, mean carotid intima-media thicknes.
(TIFF 164 kb)
Additional file 4: Figure S3. Screening procedure of total studied
subjects. The final study group consisted of 10 cases with mild SCH, 10
cases with significant SCH and 10 age- and sex- matched euthyroid
subjects. Abbreviation: mild SCH, mild subclinical hypothyroidism group;
significant SCH, significant subclinical hypothyroidism group.
(TIFF 2641 kb)
Additional file 5: Figure S4. FPLC elution profiles for a representative
plasma sample from a hypercholesterolemic complicated with
hypertriglyceridemic individual. A: The elution volume, in milliliters, is
represented on the χ-axis and the UV absorbance units (mAU), measured
at 280 nm, are represented by the y-axis. B: The elution volume, in
milliliters, is represented on the χ-axis and the concentrations of TC and
TG are represented by the y-axis. The elution volume for VLDL ranges
from 7 to 9 ml, from 9 to 13 ml for LDL, and from 13 ml to 17.5 ml for
HDL. (TIFF 563 kb)
Additional file 6: Figure S5. SRM of HODEs and HETEs from plasma or
LDL. The transitions monitored were mass-to-charge ratio (m/z): 295.0→
171.0 for 9-HODE; 295.1→ 194.8 for 13-HODE; 299.0→ 197.9 for 13(S)-
HODE-d4; 319.1→ 115.0 for 5-HETE; 319.0→ 179.0 for 12-HETE; 319.1→
175.0 for 15-HETE; 327.1→ 226.1 for 15(S)-HETE-d8. (TIFF 1255 kb)
Abbreviations
SCH: Subclinical hypothyroidism; HODEs: Hydroxy-octadecadienoic acids;
HETEs: Hydroxy-eicosatetraenoic acids; HPODE: Hydroperoxyoctadecadienoic
acid; HPETE: Hydroperoxyeicosatetraenoic acid; IMT: Intima-media thickness;
TSH: Thyroid-stimulating hormone; FT4: Free thyroxine; FT3: Free
triiodothyronine; FBG: Fasting blood glucose; TC: Total cholesterol;
TG: Triglyceride; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High-
density lipoprotein cholesterol; FPLC: Fast–protein liquid chromatography;
LC-ESI-MS: Liquid chromatograph-electrospray ionization- mass spectrometer.
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